ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $4.50.

ALXO has been the subject of several recent analyst reports. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research note on Monday, December 22nd. UBS Group began coverage on ALX Oncology in a research note on Friday, March 6th. They issued a “buy” rating and a $6.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of ALX Oncology in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Finally, Piper Sandler lifted their price objective on ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO opened at $2.17 on Wednesday. The stock has a market cap of $117.66 million, a price-to-earnings ratio of -1.14 and a beta of 0.47. The stock’s 50-day moving average is $1.91 and its 200 day moving average is $1.60. The company has a current ratio of 2.07, a quick ratio of 2.07 and a debt-to-equity ratio of 0.17. ALX Oncology has a 1-year low of $0.40 and a 1-year high of $2.66.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Monday, March 9th. The company reported ($0.42) EPS for the quarter. On average, sell-side analysts anticipate that ALX Oncology will post -2.76 EPS for the current fiscal year.

Insider Buying and Selling

In other ALX Oncology news, Director Corey S. Goodman bought 3,184,713 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was acquired at an average price of $1.57 per share, with a total value of $4,999,999.41. Following the completion of the purchase, the director owned 8,453,038 shares of the company’s stock, valued at approximately $13,271,269.66. This trade represents a 60.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 21.00% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. bought a new stake in shares of ALX Oncology in the 3rd quarter worth $1,195,000. Renaissance Technologies LLC lifted its holdings in shares of ALX Oncology by 157.2% during the fourth quarter. Renaissance Technologies LLC now owns 423,099 shares of the company’s stock valued at $478,000 after purchasing an additional 258,600 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of ALX Oncology during the second quarter valued at $84,000. Acadian Asset Management LLC boosted its position in shares of ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after buying an additional 186,883 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in ALX Oncology by 26.9% in the 3rd quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after buying an additional 128,737 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.